This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Targeted Brain Tumor Radiotherapy Using an Auger Emitter
- Targeted brain tumor radiotherapy using an Auger emitter
- Targeted Chemoradiation in Metastatic Colorectal Cancer: A Phase I Trial of 131I-huA33 with Concurrent Capecitabine
- 124I-huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET
- Therapeutic Antibody Targeting of CD97 in Experimental Arthritis: the Role of Antigen Expression, Shedding, and Internalization on the Pharmacokinetics of Anti-CD97 Monoclonal Antibody 1B2
- Therapy of Small Subcutaneous B-Lymphoma Xenografts with Antibodies Conjugated to Radionuclides Emitting Low-Energy Electrons
- Current Status of Therapy of Solid Tumors
- In vitro Toxicity of A-431 Carcinoma Cells with Antibodies to Epidermal Growth Factor Receptor and Epithelial Glycoprotein-1 Conjugated to Radionuclides Emitting Low-Energy Electrons
- Specific and High-Level Targeting of Radiolabeled Octreotide Analogues to Human Medulloblastoma Xenografts
- A Comparison of 4 Radionuclides Conjugated to Antibodies for Single-Cell Kill
- Preliminary Report of a Phase I Study of Combination Chemotherapy and Humanized A33 Antibody Immunotherapy in Patients with Advanced Colorectal Cancer
- Phase I Study of Anticolon Cancer Humanized Antibody A33
- Intracellular Accumulation of the Anti-CD20 Antibody 1F5 in B-Lymphoma Cells
- Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33
- Relative Therapeutic Efficacy of 125I- and 131I-Labeled Monoclonal Antibody A33 in a Human Colon Cancer Xenograft
- Single-cell Cytotoxicity with Radiolabeled Antibodies
- The human A33 antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily